Form 4: Pacira BioSciences Director Gary W. Pace Sells Shares in Multiple Transactions

Director Gary W. Pace of Pacira BioSciences, Inc. reported selling a significant number of shares in a series of transactions between March 6 and March 8, 2024.

Summary

• Gary W. Pace, a director of Pacira BioSciences, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 6, 2024, Pace sold 1,066 shares of common stock at a price of $29.67 per share.
• On March 7, 2024, he sold 28,257 shares at a weighted average price of $30.81 per share, with prices ranging from $30.550 to $30.965.
• On March 8, 2024, Pace sold 90,000 shares at a weighted average price of $30.60 per share, with prices ranging from $30.300 to $30.860.
• Following these transactions, Pace directly owns 22,127 shares of Pacira BioSciences, Inc. common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock sales by a director. It doesn't inherently convey positive or negative sentiment, but the market's reaction to insider sales can vary.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry. Investors often monitor these filings for insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Comparing Pace's transactions to similar insider sales at companies like Teva Pharmaceutical Industries Ltd. or Mylan N.V. (now Viatris) would provide context.
• Analyzing the volume and timing of these sales relative to Pacira's stock performance and industry trends can offer insights into whether these transactions are typical or indicative of a specific outlook.

Stakeholder Impact

• Shareholders may interpret the stock sales as a signal, although it's important to consider the context and the director's overall holdings.
• The transactions could have a minor impact on the stock price in the short term.

Key Dates